Vericel Corporation

VCEL US

VCEL USVericel Corporation

United States Composite

43.04

USD

-0.33

(-0.76%)

0.01EPS Dil.

4,304.00P/E

2.07BMarket Cap

Next Earnings

February 21

Held by Insiders

0.82%

Held by Institutions

108.94%

Short % of Float

12.59%

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.01	0.01	0.01	2.47	2.15	2.35	1.92	2.26	2.67	2.75	3.36	3.49	4.15	4.35
Basic EPS, GAAP	-10.19	-14.31	-5.18	-1.71	-0.69	-0.85	-0.52	-0.2	-0.22	0.06	-0.16	-0.35	-0.07	0.01
Free Cash Flow per Basic Share	-13.22	-14.47	-6.63	-2.25	-0.66	-0.92	-0.44	-0.08	-0.22	0.33	0.45	0.21	0.01	0.04
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	-6.71	-14.66	-7.3	-0.11	-0.68	-0.44	0.62	2.34	2.48	2.93	3.64	4.09	4.73	4.83
Tangible Book Value per Share	-6.71	-14.66	-7.3	-0.25	-0.94	-0.43	0.63	2.35	2.48	2.93	3.64	3.91	4.58	4.69
Basic Weighted Avg Shares	2	2	3	12	24	23	33	40	44	45	46	47	48	48
Sales/Revenue/Turnover	- -	- -	- -	29	51	54	64	91	118	124	156	164	198	208
Operating Margin (%)	-161,333.33	-160,761.9	-110,336.84	-81.73	-32.58	-30.54	-23.44	-4.3	-9.55	1.91	-5.03	-10.38	-3.27	-1.81
Depreciation Expense	1	1	- -	1	2	2	2	1	2	2	3	4	5	5
Net Income, GAAP	-20	-29	-16	-20	-16	-20	-17	-8	-10	3	-7	-17	-3	- -
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	5.91	- -	- -	- -	64.35
Profit Margin (%)	-109,266.67	-140,352.38	-82,221.05	-69.18	-31.93	-35.98	-27.04	-8.96	-8.2	2.31	-4.78	-10.17	-1.61	0.22
Working Capital	-14	8	3	30	15	32	37	98	92	101	132	149	160	153
LT Debt	- -	- -	- -	- -	- -	9	17	- -	22	49	47	43	82	86
Total Equity	-13	10	4	36	22	25	23	102	111	134	170	192	226	234
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	1.37	- -	- -	- -	-0.47
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	1.76	- -	- -	- -	0.24
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	-13.09	-9.07	2.33	-4.9	-9.18	-1.52	0.21

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	15,168.78%	17.25%	20.17%
Net Income, GAAP	-46.43%	-85.8%	-80.96%
Free Cash Flow	-22.68%	-28.67%	-97.05%
Total Cash Common Dividend	- -	- -	- -
Total Equity	122.06%	17.36%	17.52%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Dominick C. Colangelo Esq.
Full Time Employees: 305
Sector: Healthcare
Industry: Biotechnology
Address: 64 Sidney Street Cambridge MA United States 02139
IPO Date: Feb 4, 1997
Website: vcel.com
Business: Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Company News

GuruFocus.com
4 days ago
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
benzinga
4 days ago
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
GuruFocus.com
24 days ago
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
Yahoo Finance
24 days ago
Vericel to Present at the Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024
Yahoo Finance
a month ago
Vericel Corporation (NASDAQ:VCEL) Q1 2024 Earnings Call Transcript
Yahoo Finance
a month ago
Vericel First Quarter 2024 Earnings: Beats Expectations
Yahoo Finance
a month ago
Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...
GuruFocus.com
a month ago
Vericel Corp (VCEL) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and Strategic Expansions
GuruFocus.com
a month ago
Q1 2024 Vericel Corp Earnings Call Transcript
Yahoo Finance
a month ago
Q1 2024 Vericel Corp Earnings Call
Yahoo Finance
a month ago
Vericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core Markets
GuruFocus.com
a month ago
Vericel Corp (VCEL) Surpasses Q1 Revenue Forecasts with Strong Growth in Core Markets
Yahoo Finance
a month ago
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance
Yahoo Finance
2 months ago
Here's Why Shareholders May Want To Be Cautious With Increasing Vericel Corporation's (NASDAQ:VCEL) CEO Pay Packet
GuruFocus.com
2 months ago
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
Yahoo Finance
2 months ago
Vericel to Report First-Quarter 2024 Financial Results on May 8, 2024
Yahoo
3 months ago
Director ZERBE ROBERT L MD Sells Shares of Vericel Corp (VCEL)
Yahoo
3 months ago
Land Developer And A Specialty Medical Stock Burst Into Buy Zones

	Sep'23	Dec'23	Mar'24
ST Debt	7	6	6
LT Borrowings	- -	- -	- -
LT Finance Leases	78	82	86
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	48	48	48
Market Capitalization	1,640	1,725	2,543

	Sep'23	Dec'23	Mar'24
Total Current Assets	186	206	190
Accounts Receivable, Net	40	58	50
Cash, Cash Equivalents & STI	105	110	111
Inventories	13	13	14
Total Current Liabilities	36	46	36
Payables & Accruals	19	26	23
ST Debt	7	6	6
Deferred Revenue	- -	- -	- -

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	0.01	0.01	0.01	2.47	2.15	2.35	1.92	2.26	2.67	2.75	3.36	3.49	4.15	4.35
Basic EPS, GAAP	-10.19	-14.31	-5.18	-1.71	-0.69	-0.85	-0.52	-0.2	-0.22	0.06	-0.16	-0.35	-0.07	0.01
Free Cash Flow per Basic Share	-13.22	-14.47	-6.63	-2.25	-0.66	-0.92	-0.44	-0.08	-0.22	0.33	0.45	0.21	0.01	0.04
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	-6.71	-14.66	-7.3	-0.11	-0.68	-0.44	0.62	2.34	2.48	2.93	3.64	4.09	4.73	4.83
Tangible Book Value per Share	-6.71	-14.66	-7.3	-0.25	-0.94	-0.43	0.63	2.35	2.48	2.93	3.64	3.91	4.58	4.69
Basic Weighted Avg Shares	2	2	3	12	24	23	33	40	44	45	46	47	48	48
Sales/Revenue/Turnover	- -	- -	- -	29	51	54	64	91	118	124	156	164	198	208
Operating Margin (%)	-161,333.33	-160,761.9	-110,336.84	-81.73	-32.58	-30.54	-23.44	-4.3	-9.55	1.91	-5.03	-10.38	-3.27	-1.81
Depreciation Expense	1	1	- -	1	2	2	2	1	2	2	3	4	5	5
Net Income, GAAP	-20	-29	-16	-20	-16	-20	-17	-8	-10	3	-7	-17	-3	- -
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	5.91	- -	- -	- -	64.35
Profit Margin (%)	-109,266.67	-140,352.38	-82,221.05	-69.18	-31.93	-35.98	-27.04	-8.96	-8.2	2.31	-4.78	-10.17	-1.61	0.22
Working Capital	-14	8	3	30	15	32	37	98	92	101	132	149	160	153
LT Debt	- -	- -	- -	- -	- -	9	17	- -	22	49	47	43	82	86
Total Equity	-13	10	4	36	22	25	23	102	111	134	170	192	226	234
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	1.37	- -	- -	- -	-0.47
Return on Capital (%)	- -	- -	- -	- -	- -	- -	- -	- -	- -	1.76	- -	- -	- -	0.24
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	-13.09	-9.07	2.33	-4.9	-9.18	-1.52	0.21

Year	Q1	Q2	Q3	Q4	FY
2022	-0.15	-0.19	-0.14	0.13	-0.35
2023	-0.16	-0.11	-0.08	0.27	-0.07
2024	-0.08	- -	- -	- -	- -